Evidence map›Paper›PMID 34193050›Full record

ReviewBiological procedures online2021

Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines.

Ali Azadi, Alireza Golchini, Sina Delazar, Fatemeh Abarghooi Kahaki, Seyed Mohsen Dehnavi, Zahra Payandeh, Shirin Eyvazi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biological procedures online, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. The next generation of immunotherapies for lung cancers.Nature reviews. Clinical oncology · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Gut microbiome: decision-makers in the microenvironment of colorectal cancer.Frontiers in cellular and infection microbiology · 2023
    Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Ali AzadiDepartment of Medicine, De La Salle Health Sciences Institute, Dasmariñas, Philippines.
Alireza GolchiniCancer surgery Department; Shiraz Medical School, Shiraz University of medical Sciences, Shiraz, Iran.
Sina DelazarDepartment of Radiology, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh Abarghooi KahakiDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyed Mohsen DehnaviFaculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Zahra PayandehImmunology Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Zpayandeh58@yahoo.com.
Shirin EyvaziDepartment of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran. shirin_biotech@yahoo.com.
Cancer Clinic · USDe La Salle University – Dasmariñas · PHIslamic Azad University of Tabriz · IRShahid Beheshti University · IRShahid Beheshti University of Medical Sciences · IRTabriz University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a universal heterogeneous disease that is characterized by genetic and epigenetic alterations. Immunotherapy using monoclonal antibodies (mAb) and cancer vaccines are substitute strategies for CRC treatment. When cancer immunotherapy is combined with chemotherapy, surgery, and radiotherapy, the CRC treatment would become excessively efficient. One of the compelling immunotherapy approaches to increase the efficiency of CRC therapy is the deployment of therapeutic mAbs, nanobodies, bi-specific antibodies and cancer vaccines, which improve clinical outcomes in patients. Also, among the possible therapeutic approaches for CRC patients, gene vaccines in combination with antibodies are recently introduced as a new perspective. Here, we aimed to present the current progress in CRC immunotherapy, especially using Bi-specific antibodies and dendritic cells mRNA vaccines. For this aim, all data were extracted from Google Scholar, PubMed, Scopus, and Elsevier, using keywords cancer vaccines; CRC immunotherapy and CRC mRNA vaccines. About 97 articles were selected and investigated completely based on the latest developments and novelties on bi-specific antibodies, mRNA vaccines, nanobodies, and MGD007.

Indexed as

Bi-specific antibodyCancer vaccinesColorectal cancerMGD007mRNA vaccinesNanobodies

Identifiers

PMID34193050
PMCPMC8245152
OpenAlexW3177151356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.